Cargando…

Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold

BACKGROUND: The common cold, the most prevalent contagious viral disease in humans still lacks a safe and effective antiviral treatment. Iota-Carrageenan is broadly active against respiratory viruses in-vitro and has an excellent safety profile. This study investigated the efficacy and safety of an...

Descripción completa

Detalles Bibliográficos
Autores principales: Eccles, Ron, Meier, Christiane, Jawad, Martez, Weinmüllner, Regina, Grassauer, Andreas, Prieschl-Grassauer, Eva
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923116/
https://www.ncbi.nlm.nih.gov/pubmed/20696083
http://dx.doi.org/10.1186/1465-9921-11-108
_version_ 1782185477576589312
author Eccles, Ron
Meier, Christiane
Jawad, Martez
Weinmüllner, Regina
Grassauer, Andreas
Prieschl-Grassauer, Eva
author_facet Eccles, Ron
Meier, Christiane
Jawad, Martez
Weinmüllner, Regina
Grassauer, Andreas
Prieschl-Grassauer, Eva
author_sort Eccles, Ron
collection PubMed
description BACKGROUND: The common cold, the most prevalent contagious viral disease in humans still lacks a safe and effective antiviral treatment. Iota-Carrageenan is broadly active against respiratory viruses in-vitro and has an excellent safety profile. This study investigated the efficacy and safety of an Iota-Carrageenan nasal spray in patients with common cold symptoms. METHODS: In a randomized, double-blind, placebo-controlled exploratory trial, 35 human subjects suffering from early symptoms of common cold received Iota-Carrageenan (0.12%) in a saline solution three times daily for 4 days, compared to placebo. RESULTS: Administration of Iota-Carrageenan nasal spray reduced the symptoms of common cold (p = 0.046) and the viral load in nasal lavages (p = 0.009) in patients with early symptoms of common cold. Pro-inflammatory mediators FGF-2, Fractalkine, GRO, G-CSF, IL-8, IL-1α, IP-10, IL-10, and IFN-α2 were reduced in the Iota-Carrageenan group. CONCLUSIONS: Iota-Carrageenan nasal spray appears to be a promising treatment for safe and effective treatment of early symptoms of common cold. Larger trials are indicated to confirm the results.
format Text
id pubmed-2923116
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29231162010-08-18 Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold Eccles, Ron Meier, Christiane Jawad, Martez Weinmüllner, Regina Grassauer, Andreas Prieschl-Grassauer, Eva Respir Res Research BACKGROUND: The common cold, the most prevalent contagious viral disease in humans still lacks a safe and effective antiviral treatment. Iota-Carrageenan is broadly active against respiratory viruses in-vitro and has an excellent safety profile. This study investigated the efficacy and safety of an Iota-Carrageenan nasal spray in patients with common cold symptoms. METHODS: In a randomized, double-blind, placebo-controlled exploratory trial, 35 human subjects suffering from early symptoms of common cold received Iota-Carrageenan (0.12%) in a saline solution three times daily for 4 days, compared to placebo. RESULTS: Administration of Iota-Carrageenan nasal spray reduced the symptoms of common cold (p = 0.046) and the viral load in nasal lavages (p = 0.009) in patients with early symptoms of common cold. Pro-inflammatory mediators FGF-2, Fractalkine, GRO, G-CSF, IL-8, IL-1α, IP-10, IL-10, and IFN-α2 were reduced in the Iota-Carrageenan group. CONCLUSIONS: Iota-Carrageenan nasal spray appears to be a promising treatment for safe and effective treatment of early symptoms of common cold. Larger trials are indicated to confirm the results. BioMed Central 2010 2010-08-10 /pmc/articles/PMC2923116/ /pubmed/20696083 http://dx.doi.org/10.1186/1465-9921-11-108 Text en Copyright ©2010 Eccles et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Eccles, Ron
Meier, Christiane
Jawad, Martez
Weinmüllner, Regina
Grassauer, Andreas
Prieschl-Grassauer, Eva
Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold
title Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold
title_full Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold
title_fullStr Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold
title_full_unstemmed Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold
title_short Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold
title_sort efficacy and safety of an antiviral iota-carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923116/
https://www.ncbi.nlm.nih.gov/pubmed/20696083
http://dx.doi.org/10.1186/1465-9921-11-108
work_keys_str_mv AT ecclesron efficacyandsafetyofanantiviraliotacarrageenannasalsprayarandomizeddoubleblindplacebocontrolledexploratorystudyinvolunteerswithearlysymptomsofthecommoncold
AT meierchristiane efficacyandsafetyofanantiviraliotacarrageenannasalsprayarandomizeddoubleblindplacebocontrolledexploratorystudyinvolunteerswithearlysymptomsofthecommoncold
AT jawadmartez efficacyandsafetyofanantiviraliotacarrageenannasalsprayarandomizeddoubleblindplacebocontrolledexploratorystudyinvolunteerswithearlysymptomsofthecommoncold
AT weinmullnerregina efficacyandsafetyofanantiviraliotacarrageenannasalsprayarandomizeddoubleblindplacebocontrolledexploratorystudyinvolunteerswithearlysymptomsofthecommoncold
AT grassauerandreas efficacyandsafetyofanantiviraliotacarrageenannasalsprayarandomizeddoubleblindplacebocontrolledexploratorystudyinvolunteerswithearlysymptomsofthecommoncold
AT prieschlgrassauereva efficacyandsafetyofanantiviraliotacarrageenannasalsprayarandomizeddoubleblindplacebocontrolledexploratorystudyinvolunteerswithearlysymptomsofthecommoncold